The Story
News Summary
- Johnson & Johnson raised its 2026 financial targets, projecting 6.5% sales growth and adjusted EPS growth of 7.3%, topping $100 billion in revenue.
- Despite STELARA biosimilar headwinds, management anticipates accelerating double-digit growth by 2030, powered by its robust oncology, immunology, and MedTech product pipelines.
Explore US30 price history & advisor snapshot
These are separate market snapshots and may predate this story. Check the data period, generation time and expiry before using them in your research.
Stored market data
US30 price history
52421.20
+11.27% over the displayed period
Advisor Snapshot
Unlock Member-Only Insights
Reserved for TradingNews24 members. Log in or create a free account to access market signals and exclusive tools.